Search Results
May 13, 2024, 06:35 ET Hyderabad-Based IT Company Distributes Umbrellas to Voters to Beat the Heat
company. RBT offers comprehensive end-to-end IT Solutions in Gen-AI, Enterprise Collaboration Solutions, Web Applications, Cloud Computing and IT Infrastructure Management to Retail, Banking & Finance, Healthcare, Media & Broadcasting, Agritech, Pharma & Life Science verticals. RBT is having
More news about: Ray Business Technologies
Apr 26, 2024, 08:00 ET Renibus Therapeutics Announces Oral Presentations on RBT-1 at AATS and SCA Medical Conferences
evaluating RBT-1's potential to reduce the risk of post operative complications and improve outcomes following cardiothoracic surgery. RBT-1 has received both FDA Breakthrough and Fast Track Designations. Details of the oral presentations at AATS: Title: RBT-1 Reduces Incidence
More news about: Renibus Therapeutics
Apr 18, 2024, 08:00 ET Renibus Therapeutics Announces Oral Presentation on RBT-1 at the European Association for Cardio-Thoracic Surgery (EACTS) 2nd Innovation Summit
Medicine, added, "RBT-1 is an exciting pre-conditioning agent and I am honored to showcase its results at EACTS. While RBT-1 has demonstrated its potential benefit across multiple cardiac surgery types in its Phase 2 clinical trial, I look forward to presenting data demonstrating RBT-1's potential to have
More news about: Renibus Therapeutics
Apr 16, 2024, 10:00 ET Midwest Autism & Therapy Centers Welcomes New Board Certified Behavior Analysts (BCBAs) to Their Iowa-Based Campuses
education in Applied Behavior Analysis at Capella University. Prior to sitting for her board exams, Shayna worked as a Registered Behavior Technician (RBT) with children on the Autism Spectrum. Her areas of expertise include behavior shaping, differential reinforcement, and teaching verbal behavior.
More news about: Midwest Autism & Therapy Centers
Apr 02, 2024, 16:05 ET Renibus Announces Participation at the 23rd Annual Needham Virtual Healthcare Conference
improve outcomes and protect against organ damage associated with cardio, renal and metabolic diseases. Renibus' first-in-a-new class lead program is RBT-1 (stannic protoporfin / iron sucrose), a single dose IV drug that is given over 1-2 hours, 24-48 hours prior to patients undergoing elective cardiac
More news about: Renibus Therapeutics
Mar 21, 2024, 08:00 ET Renibus Announces Leadership Transition
exploring opportunities to further the clinical development of RBT-3 in these potential indications. RBT-9 (stannic protoporfin), another component of RBT-1, is a potent anti-inflammatory and antioxidant drug. It has completed Phase 1 (as part of the RBT-1 program) and has been investigated in a 42-patient Phase
More news about: Renibus Therapeutics
Feb 22, 2024, 16:05 ET Renibus Therapeutics to Present at the Evercore ISI 2024 Emerging Biotech Conference
exploring opportunities to further the clinical development of RBT-3 in these potential indications. RBT-9 (stannic protoporfin), another component of RBT-1, is a potent anti-inflammatory and antioxidant drug. It has completed Phase 1 (as part of the RBT-1 program) and has been investigated in a 42-patient Phase
More news about: Renibus Therapeutics
Feb 20, 2024, 09:07 ET Introducing Little Hands Day Program: An Alternative to Preschool for Children with Autism by Helping Hands Family
program include: Experienced Autism Specialist Team: Certified ABA therapists, including Registered Behavior Technicians (RBT) and Board-Certified Behavior Analysts (BCBA), specializing in autism and early child development.Individualized Curriculum: Customized
More news about: Helping Hands Family
Feb 07, 2024, 16:05 ET Renibus Therapeutics Announces Presentation at Oppenheimer 34th Annual Healthcare Conference
exploring opportunities to further the clinical development of RBT-3 in these potential indications. RBT-9 (stannic protoporfin), another component of RBT-1, is a potent anti-inflammatory and antioxidant drug. It has completed Phase 1 (as part of the RBT-1 program) and has been investigated in a 42-patient Phase
More news about: Renibus Therapeutics
Jan 29, 2024, 08:39 ET Championing Access: Autism Partnership Foundation Free Training Has Reached Over 530,000 Worldwide
person, forever. The training was designed for professionals interested in pursuing the requirements to obtain the Registered Behavior Technician (RBT) certification, but to the surprise of APF staff, the training also became highly sought after by teachers and school district staff, paraprofessionals,
More news about: Autism Partnership Foundation
Jan 18, 2024, 11:04 ET "Revolutionizing Live-in Developmental Child Care: Apex Social Group Showcases their Care Professionals at Special Needs Resource Fairs"
assisting families with children who have special needs, Apex Social's "Apex Care Professionals" have backgrounds in pediatric nursing, special education, RBT, occupational and physical therapy, and speech therapy. The organization offers a boutique-style service experience that goes beyond traditional nanny
More news about: Apex Social Group
Jan 09, 2024, 08:00 ET Renibus Announces Publication of Results from Phase 2 Study Evaluating RBT-1 as a Pre-Conditioning Agent to Reduce Post-Operative Complications Following Cardiothoracic Surgery
exploring opportunities to further the clinical development of RBT-3 in these potential indications. RBT-9 (stannic protoporfin), another component of RBT-1, is a potent anti-inflammatory and antioxidant drug. It has completed Phase 1 (as part of the RBT-1 program) and has been investigated in a 42-patient Phase
More news about: Renibus Therapeutics
Jan 04, 2024, 10:37 ET SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Rubicon Technologies, Inc. (NYSE: RBT)
Jan. 4, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Rubicon Technologies, Inc. (NYSE: RBT) on behalf of the company's shareholders. The investigation seeks to determine whether Rubicon Technologies's directors breached their fiduciary duties
More news about: Purcell & Lefkowitz LLP
Oct 25, 2023, 08:00 ET Renibus Announces First Patient Enrolled in PROTECT Phase 3 Study of RBT-1 to Reduce Post-operative Complications After Cardiothoracic Surgery
treatment option forward for patients undergoing cardiac surgery. RBT-1 is a potentially transformational pre-conditioning product, and I am enthusiastic about the initial results demonstrated in our patients." About RBT-1 RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of
More news about: Renibus Therapeutics
Oct 10, 2023, 16:05 ET Renibus Therapeutics Announces Participation at Upcoming Investor Conferences
lead program is RBT-1, a drug that will enter a Phase 3 pivotal trial in cardiothoracic surgery in Q4 2023. RBT-3 is a novel, low molecular weight iron nanoparticle that has the potential to rapidly resolve iron deficiency and may reduce the risk of cisplatin-induced nephrotoxicity. RBT-9 (stannic protoporfin)
More news about: Renibus Therapeutics
Oct 03, 2023, 09:07 ET Start Your Career in Behavioral Healthcare with Helping Hands Family Autism Services
behaviors, and improve their quality of life. What does an RBT do? RBTs implement specific tasks/goals with their client that are laid out in the behavior care plan created by BCBAs. Through play-based therapy tactics, an RBT observes and takes notes on a child's progression with the goals.
More news about: Helping Hands Family
Sep 12, 2023, 08:00 ET Renibus Therapeutics Announces Final Close of Upsized Series B Financing, Bringing Total Round to $72 Million
sufficient runway to advance RBT-1 through the planned Phase 3 trial and preparation for an NDA filing. The upsized round is also expected to enable us to selectively fund additional pipeline programs with the potential for further value creation." About RBT-1 RBT-1 (stannic protoporfin/iron
More news about: Renibus Therapeutics
Sep 11, 2023, 08:00 ET Renibus Presents Phase 2 Results on RBT-1, a First-in-Class Preconditioning Agent, at the American Society for Enhanced Recovery and Perioperative Medicine (ASER PM) 2023 Meeting
observed in the RBT-1 group compared with placebo (RBT-1: 0.0% vs Placebo: 12.2%; p=0.0046).Importantly, hemoglobin levels at discharge in patients who received RBT-1 were comparable to those who received placebo despite lesser rates of blood transfusion and iron supplementation (RBT-1: 9.8 g/dL vs
More news about: Renibus Therapeutics
Aug 03, 2023, 09:31 ET Thinking about buying stock in T Stamp, AgriFORCE Growing Systems, Driven Brands Holdings, Rubicon Technologies, or Quantum Computing?
Aug. 3, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IDAI, AGRI, DRVN, RBT, and QUBT.
More news about: InvestorsObserver
Jul 18, 2023, 08:00 ET Renibus Therapeutics Announces $47 Million Financing to Advance Lead Program RBT-1 Through Pivotal Phase 3 Trial
protection via preconditioning. Renibus' first-in-class lead program is RBT-1. RBT-2 is an antioxidant and anti-fibrotic drug that has been shown in pre-clinical models to have the potential to reduce the risk of CKD progression. RBT-3 is a novel, low molecular weight iron nanoparticle that has the potential
More news about: Renibus Therapeutics
Jul 11, 2023, 08:00 ET Renibus Therapeutics Announces Breakthrough Therapy Designation from US FDA for RBT-1 for the Reduction in Risk of Post-Operative Complications in Patients Undergoing Cardiothoracic Surgery
-Agreement reached with FDA for Phase 3 pivotal trial for RBT-1- RBT-1 is a first-in-class, pre-conditioning drug in the cardiothoracic surgery setting--Company to initiate pivotal Phase 3 study of RBT-1 in Q3 2023-
More news about: Renibus Therapeutics